Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared a post on X:
“ASCO 25 is in 4 weeks.
Here all the oral presentations on ADCs (one table with all the topo1, the other one with all the non-topo1, mainly MMAE)
Trends: more topo1, earlier lines, combo, new indications.
Usual suspects: payloads and targets.”
